UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): MARCH 30, 2004
ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-21198 76-0233274
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
2408 TIMBERLOCH PLACE, SUITE B-10
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 719-3400
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
ITEM 5. OTHER INFORMATION
On March 30, 2004, Zonagen, Inc. (the "Company") announced in a press
release that Dr. Ronald Wiehle, the Company's Director of R&D, presented data
generated at the Company in collaboration with scientists at the University of
Illinois-Chicago that indicate the potential for Progenta(TM) for the treatment
of breast cancer. A copy of the Company's press release is attached hereto as
Exhibit 99.1. The press release is incorporated by reference herein and the
foregoing description of the press release is qualified in its entirety by
reference to the attached exhibit.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
c. Exhibits
Exhibit
Number Description
------- -----------
99.1 Press Release dated March 30, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: April 1, 2004.
By: /s/ Louis Ploth, Jr.
-------------------------------------------
Louis Ploth, Jr.
Vice President, Business Development
and Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number Description
------- -----------
99.1 Press Release dated March 30, 2004.